|Articles|October 1, 2013

PE June 2013 BPA

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

Pharmaceutical Executive Daily: Organon CEO Kevin Ali Resigns

ByNicholas Jacobus

October 28th 2025

GSK Enters $745 Million Worldwide Exclusive License Agreement with Empirico for Clinical-Stage First-In-Class Oligonucleotide Candidate

ByNicholas Jacobus

October 28th 2025

Image Credit: Adobe Stock Images/David A Litman

FDA Approves Single-Injection, Once-Monthly Maintenance Regimen for Lilly’s Omvoh in Ulcerative Colitis

ByDavy James

October 28th 2025

Roundup: Pharma Funding Continues with Financing Rounds and Public Offering Price Announcements

ByNicholas Jacobus

October 28th 2025

Image Credit: Adobe Stock Images/Designpics

FDA Expands Indication for Merck’s Winrevair in Pulmonary Arterial Hypertension

ByDavy James

October 28th 2025

PE June 2013 BPA

Newsletter

Related Content

Pharmaceutical Executive Daily: Organon CEO Kevin Ali Resigns

GSK Enters $745 Million Worldwide Exclusive License Agreement with Empirico for Clinical-Stage First-In-Class Oligonucleotide Candidate

FDA Approves Single-Injection, Once-Monthly Maintenance Regimen for Lilly’s Omvoh in Ulcerative Colitis

Roundup: Pharma Funding Continues with Financing Rounds and Public Offering Price Announcements

FDA Expands Indication for Merck’s Winrevair in Pulmonary Arterial Hypertension

Trending on PharmExec

Organon CEO Kevin Ali to Resign Following Internal Investigation into Nexplanon Sales

Study Claims Ozempic Lowers Biological Age

How will DTC Programs Impact PBMs?

Novartis Enters $12 Billion Definitive Merger Agreement to Acquire Avidity Biosciences

GSK Agrees to $357 Million Exclusive License Agreement for Syndivia’s AntiBody-Drug Conjugate